Conclusion:
Our study demonstrates that F-araA PK does not predict HCT outcome in
patients with high-risk TM. NT5E promoter polymorphism could be a
predictive biomarker in F-araA based HCT setting in TM; however,
extensive functional studies are warranted to validate the clinical
utility of this finding.